Cadila Healthcare, has executed an asset purchase agreement with a commercial-stage biopharmaceutical company, BridgeBio Pharma where the former’s US-based biopharmaceutical subsidiary Sentynl Therapeutics will acquire BridgeBio’s NULIBRY (Fosdenopterin) for Injection.
1 Like